West Pharmaceutical Services (WST)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$339.97-0.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · WST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 29.8% |
| Our one-year growth estimate | diamond | 5.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 24.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers
WST — CEO transition
Dated 2026-06-01
President and Chief Executive Officer — Eric M. Green: Mr. Eric M. Green is retiring from his roles as President, CEO, and Chair of the Board after a successor has been hired.
Why it matters: The sale's completion changes revenue expectations. It also affects focus for the year.
Supportive ifAnnouncement of the successful sale of SmartDose® 3.5mL to AbbVie.
Worry ifDelay or cancellation of the SmartDose® 3.5mL sale.
Why it matters: The new CEO's vision could shift company priorities and affect future growth.
Watch forA strategic plan was announced. It shows growth ideas and market focus.
Also watch forNo clear strategic direction or plan announced by the new CEO.
Why it matters: Changes to revenue guidance show the company's growth and market demand. It shows management's trust in future sales.
Supportive ifFull-year 2026 revenue guidance remains in the range of $3.295 billion to $3.350 billion.
Worry ifFull-year 2026 revenue guidance is now below $3.295 billion.
Why it matters: The new CEO's vision may change the company's direction and growth strategy.
Watch forMichel Lagarde outlines a clear growth strategy in a press release.
Also watch forThe new CEO fails to communicate a coherent strategy or vision.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$94 on $10,000 · ±0.9% | How much price usually moves either way. |
| Bad day | $300 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,470 loss on $10,000 · 24.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Raising EPS guidance shows strong performance. This boosts investor confidence.
Supportive ifFor all of 2026, adjusted-diluted EPS is now above $9.05.
Worry ifEPS guidance remains unchanged or is lowered below $8.85.
Why it matters: Weak organic growth could signal a slowdown in the High Value Product Components business.
Worry ifQ3 2026 organic sales growth was below 7.0%.
Less concerning ifQ3 2026 organic sales growth was above 8.9%.
Why it matters: This leadership change may change the company's plans and results in the future.
Watch forMichel Lagarde becomes CEO on August 31, 2026.
Also watch forThe transition is delayed or does not occur as planned.
Why it matters: Ongoing share buybacks can show management's trust in the company's value.
Supportive ifThe company buys back shares in Q3 2026, continuing its program.
Worry ifNo shares are repurchased in Q3 2026.
Why it matters: If sales growth falls short, it may signal weakening demand or execution issues.
Worry ifQ3 2026 net sales growth reported below 1.9%.
Less concerning ifQ3 2026 net sales growth exceeds 3.8%.
Why it matters: A smooth transition is key for stability. It can affect investor confidence.
Watch forAnnouncement of a new CEO who is well-regarded in the industry.
Also watch forThere is ongoing uncertainty about leadership. The new CEO may not be well received.
Why it matters: Meeting or beating this guidance shows strong demand and good execution in the business.
Supportive ifQ3 2026 net sales reported at or above $820 million.
Worry ifQ3 2026 net sales reported below $820 million.
Why it matters: Updates on share buybacks can show management's trust in the company's worth.
Supportive ifManagement says the share buyback program has bought back over 1 million shares.
Worry ifNo major share buybacks reported in the next quarter.
Why it matters: Earnings below this level may show problems in making money.
Worry ifIn Q3 2026, adjusted-diluted EPS was less than $2.14.
Less concerning ifIn Q3 2026, adjusted-diluted EPS was more than $2.24.